Ultragenyx Pharmaceutical GAAP EPS of -$1.79 misses by $0.44, revenue of $83.4M misses by $0.28M

Feb. 10, 2022 4:24 PM ETUltragenyx Pharmaceutical Inc. (RARE)By: Niloofer Shaikh, SA News Editor
  • Ultragenyx Pharmaceutical press release (NASDAQ:RARE): Q4 GAAP EPS of -$1.79 misses by $0.44.
  • Revenue of $83.4M (-8.9% Y/Y) misses by $0.28M.
  • The company expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250M and $260M and Dojolvi revenue to be between $55M and $65M.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.